CASTRATION-RESISTANT PROSTATIC CANCER
Clinical trials for CASTRATION-RESISTANT PROSTATIC CANCER explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATIC CANCER trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATIC CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, in men with metastatic castration-resistant prostate cancer (mCRPC) that has worsened despite hormone therapy. The trial aims to find safe doses and see if the drug can lower P…
Matched conditions: CASTRATION-RESISTANT PROSTATIC CANCER
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a common heartburn pill boost chemo against tough prostate cancer?
Disease control Recruiting nowThis study tests whether adding omeprazole (a common heartburn medicine) to standard chemotherapy can help control advanced prostate cancer that has stopped responding to other treatments. About 50 men with castration-resistant prostate cancer will receive either omeprazole plus …
Matched conditions: CASTRATION-RESISTANT PROSTATIC CANCER
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug MGC026 takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…
Matched conditions: CASTRATION-RESISTANT PROSTATIC CANCER
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for tough prostate cancer? early trial begins
Disease control Recruiting nowThis early-stage study tests a new drug called JANX007 in men with advanced prostate cancer that has spread and stopped responding to standard treatments. The main goal is to check safety and find the right dose. About 272 men will take part across multiple centers.
Matched conditions: CASTRATION-RESISTANT PROSTATIC CANCER
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC